Skip to content

ISRG · Intuitive Surgical

27 filings

10-K

ISRG 10-K Annual Reports

Intuitive Surgical - 27 annual reports

Filing record · 2016–202610-K1110-Q338-K100

2025
Intuitive Surgical Annual Report, Year Ended Dec 31, 2025
Intuitive Surgical Inc. (ISRG) reported robust growth in its 2025 fiscal year, with total revenue increasing by 21% to $10.1 billion. This growth was driven by a significant increase in da Vinci procedures (up 18%) and Ion procedures (up 51%), indicating strong adoption of the company's minimally invasive robotic surgical systems and diagnostic platforms. The company saw substantial growth in both systems revenue (+26%) and instruments and accessories revenue (+19%), reflecting increased unit placements for its da Vinci surgical systems, particularly the new da Vinci 5 model. The installed base of da Vinci systems grew by 12% to over 11,100 units, while the Ion system installed base increased by 24%. Despite strong revenue growth, the gross profit margin for products decreased slightly to 66.0% from 67.5% in the prior year, attributed to factors including new tariffs, higher costs associated with the da Vinci 5, and increased depreciation, though partially offset by lower excess inventory charges. Looking ahead, ISRG continues to invest heavily in research and development to drive innovation, while also navigating macroeconomic challenges such as tariffs, inflation, and supply chain constraints. The company's financial position remains strong, with over $9 billion in cash, cash equivalents, and investments, providing ample resources to fund future growth and strategic initiatives.
Feb 3, 2026
2024
Intuitive Surgical Annual Report, Year Ended Dec 31, 2024
Intuitive Surgical, Inc. (ISRG) filed its annual report for the period ending December 30, 2024, highlighting robust revenue growth and continued expansion of its da Vinci surgical system installed base. Total revenue increased by 17% to $8.4 billion, driven by a strong performance in instruments and accessories revenue (up 19%) and systems revenue (up 17%). The company also saw significant growth in its Ion endoluminal system procedures (up 78%). The da Vinci system installed base grew 15% to 9,902 units globally, with 1,526 new systems placed during the year. This growth reflects increasing adoption across key surgical specialties, particularly in general surgery, gynecology, and urology, both domestically and internationally. The company is also investing in new product development, including the next-generation da Vinci 5 system and the E-200 generator, and expanding its manufacturing capabilities. Despite strong operational performance, the company faces ongoing risks including intense competition, potential disruptions to its supply chain, regulatory complexities, and macroeconomic headwinds such as inflation and interest rate volatility. The company's significant international operations also expose it to currency fluctuations and varied regulatory environments. Management remains focused on innovation, expanding access to minimally invasive care, and optimizing its business strategy to navigate these challenges and capitalize on future growth opportunities.
Jan 31, 2025
2023
Intuitive Surgical Annual Report, Year Ended Dec 31, 2023
Intuitive Surgical Inc. (ISRG) demonstrated robust financial performance in its 2023 fiscal year, reporting a 14% increase in total revenue to $7.1 billion. This growth was primarily driven by a strong 22% increase in instruments and accessories revenue, reflecting higher da Vinci procedure volumes, which rose 22% to approximately 2.3 million procedures. The company also saw a significant 129% surge in Ion procedures. Despite flat systems revenue, the installed base of da Vinci systems grew by 14% to 8,606 units, indicating continued market penetration and utilization. The company's strategic focus on expanding its minimally invasive care ecosystem, including its Ion endoluminal system, and its commitment to innovation and customer training are key drivers of its success. While facing macroeconomic headwinds such as inflation and higher interest rates, which have impacted customer capital spending, ISRG has managed its operations effectively, maintaining a solid cash position and continuing to invest in research and development to drive future growth. The company's extensive risk factor disclosures highlight the competitive landscape, regulatory environment, and supply chain challenges as areas of ongoing attention.
Jan 31, 2024
2022
Intuitive Surgical Annual Report, Year Ended Dec 31, 2022
Intuitive Surgical, Inc. (ISRG) filed its 2022 10-K report, detailing its continued growth in a dynamic global healthcare landscape. The company saw an 18% increase in da Vinci procedures, reaching approximately 1.875 million, alongside a substantial 218% rise in Ion system procedures to 23,500. This procedural growth drove a 13% increase in instruments and accessories revenue, highlighting the recurring revenue model's strength. However, systems revenue saw a slight 1% decrease, attributed to macroeconomic pressures, particularly in the U.S., which impacted hospital capital spending, and a 6% decline in da Vinci system placements. Despite these system placement challenges, the overall installed base of da Vinci systems grew by 12% to 7,544 units, indicating ongoing market penetration and adoption. The company's financial performance in 2022 showed total revenue growth of 9% to $6.2 billion, though operating income decreased by 13% to $1.58 billion, impacted by increased investments in R&D and SG&A expenses, including higher headcount and infrastructure costs. The gross profit margin also saw a slight decrease to 67.4% from 69.3% in the prior year, influenced by rising freight and material costs and unfavorable foreign currency impacts. Looking ahead, Intuitive Surgical faces ongoing risks related to macroeconomic conditions, supply chain constraints, and potential regulatory changes. The company is actively managing these challenges by focusing on innovation, expanding its product portfolio, and investing in its global infrastructure to support long-term growth and its mission of advancing minimally invasive care.
Feb 10, 2023
2021
Intuitive Surgical Annual Report, Year Ended Dec 31, 2021
Intuitive Surgical Inc. (ISRG) filed its 2021 10-K on February 3, 2022, reporting on its business operations and financial performance. The company, a leader in robotic-assisted minimally invasive surgery, saw a significant rebound in its business in 2021 following the disruptions of the COVID-19 pandemic in 2020. Total revenue grew 31% year-over-year, driven by strong performance across all segments, including systems, instruments, and accessories, and services. The company's core business continues to be driven by the adoption and utilization of its da Vinci Surgical Systems, which saw a 28% increase in procedures performed globally in 2021. This procedural growth fueled increased demand for instruments and accessories, as well as service revenue. Management highlighted strong system demand, with a 44% increase in da Vinci Surgical System placements compared to the prior year, indicating a recovery and expansion of its installed base. The company ended the year with a robust cash position and continues to invest in research and development to expand its product offerings and address new clinical applications.
Feb 3, 2022
2020
Intuitive Surgical Annual Report, Year Ended Dec 31, 2020
Intuitive Surgical, Inc. (ISRG) reported a challenging year in 2020, impacted significantly by the COVID-19 pandemic which led to a 3% decrease in total revenue to $4.4 billion. Despite the revenue dip, the company demonstrated resilience, with procedure volumes seeing a modest 1% increase to approximately 1.24 million, driven by growth in U.S. general surgery and global urology. The company's installed base of da Vinci Surgical Systems grew by 7% to 5,989 units, indicating continued strategic expansion despite short-term pandemic-related headwinds. Looking ahead, Intuitive Surgical is focused on innovation and expanding its product portfolio, as evidenced by investments in new technologies like the Ion endoluminal system and the da Vinci SP Surgical System. The company also introduced an "Extended Use Program" for instruments to lower customer costs and is managing its operations and workforce to navigate the ongoing uncertainties. With a strong cash position of $6.87 billion as of December 31, 2020, the company is well-positioned to manage through the current environment and invest in future growth opportunities, though the full impact of the pandemic on future procedure volumes and system placements remains uncertain.
Feb 10, 2021
2019
Intuitive Surgical Annual Report, Year Ended Dec 31, 2019
Intuitive Surgical, Inc. (ISRG) demonstrated strong growth in its 2019 fiscal year, with total revenue increasing by 20% to $4.5 billion, driven by a 23% increase in instrument and accessory revenue and a 19% increase in systems revenue. The company shipped 1,119 da Vinci Surgical Systems, a 21% increase year-over-year, and expanded its installed base to 5,582 systems. Procedures performed globally increased by 18% to approximately 1.23 million. The company continues to invest heavily in research and development, with a 33% increase in R&D expenses, focusing on expanding its product offerings and improving existing technologies. The introduction of new products like the Ion endoluminal system for diagnostic procedures and continued rollout of the da Vinci SP surgical system highlight the company's commitment to innovation. Despite a slight decrease in gross profit margin to 69.4% primarily due to increased amortization expenses from acquisitions, the company maintained robust profitability with operating income growing by 15% to $1.4 billion.
Feb 7, 2020
2018
Intuitive Surgical Annual Report, Year Ended Dec 31, 2018
Intuitive Surgical Inc. (ISRG) reported strong performance in its 2018 10-K filing, with total revenue reaching $3.7 billion, a 19% increase year-over-year. This growth was primarily driven by a 20% increase in instrument and accessory revenue, fueled by an 18% rise in da Vinci procedures performed globally, and a 21% increase in systems revenue. The company expanded its installed base of da Vinci Surgical Systems to approximately 4,986 units. Despite a slight decrease in gross profit margin to 69.9% due to lower service margins, overall operating income saw a healthy 13% increase. The company also reported a significant increase in cash, cash equivalents, and investments, reaching $4.8 billion, indicating a strong liquidity position. ISRG continues to invest heavily in research and development, signaling a commitment to future innovation and growth in the minimally invasive surgery market. The company's strategy focuses on increasing patient, surgeon, and hospital value by offering advanced robotic-assisted surgical solutions. They are expanding their product portfolio with new systems like the da Vinci SP Surgical System and new instruments such as the SureForm staplers, while also navigating regulatory landscapes and competitive pressures. Key growth drivers include the expansion of da Vinci procedures in general surgery, particularly hernia repair and colorectal procedures, as well as continued strength in urology and gynecology, both domestically and internationally. The company's direct sales model in key markets, coupled with a growing installed base and recurring revenue from instruments, accessories, and services, positions it for sustained growth.
Feb 4, 2019
2017
Intuitive Surgical Annual Report, Year Ended Dec 31, 2017
Intuitive Surgical Inc. (ISRG) reported strong performance for the fiscal year ending December 31, 2017, with total revenue increasing by 16% to $3.1 billion, driven by a 16% increase in da Vinci procedures performed worldwide. The company saw significant growth in instrument and accessory revenue (up 17%) and systems revenue (up 15%). The installed base of da Vinci Surgical Systems grew by 13% to 4,409 units globally. The company also launched the da Vinci X Surgical System in May 2017, offering advanced robotic-assisted surgery capabilities at a lower cost, and received FDA clearance for it shortly after. Financially, ISRG demonstrated robust operational efficiency with a gross profit margin of 70.1%. The company's strategy of focusing on value for patients, surgeons, and hospitals continues to drive adoption across multiple surgical specialties, with general surgery and urology showing particularly strong growth. While the company repurchased a substantial amount of its stock in 2017, it maintained a strong liquidity position with $3.8 billion in cash, cash equivalents, and investments.
Feb 2, 2018
2016
Intuitive Surgical Annual Report, Year Ended Dec 31, 2016
Intuitive Surgical, Inc. (ISRG) reported strong performance for the fiscal year ending December 31, 2016, with total revenue reaching $2.7 billion, a 13% increase year-over-year. This growth was driven by a 15% increase in procedures performed globally and a 10% increase in systems revenue. Recurring revenue, comprising instruments, accessories, and services, continued to be a significant driver, making up 71% of total revenue and growing 15% to $1.9 billion, reflecting the expanding installed base of da Vinci Surgical Systems. The company shipped 537 da Vinci Surgical Systems in 2016, an increase from 492 in the prior year, bringing the total installed base to 3,919 systems globally. The company highlighted growth in general surgery procedures in the U.S. and continued strong performance in urology procedures internationally, particularly da Vinci Prostatectomy (dVP). Research and development spending increased by 21% to $239.6 million, underscoring the company's commitment to innovation and expanding its product portfolio. ISRG ended the year with a robust cash position of $4.8 billion, providing significant financial flexibility for future growth and investments.
Feb 6, 2017
2015
Intuitive Surgical Annual Report, Year Ended Dec 31, 2015
Intuitive Surgical, Inc. (ISRG) reported strong performance for the fiscal year ending December 31, 2015, with total revenue increasing 12% year-over-year to $2.4 billion. This growth was driven by a 14% increase in system revenue and an 11% increase in recurring revenue, the latter representing a consistent 70% of total revenue. The company saw a 14% rise in da Vinci procedures performed globally, reaching approximately 652,000, indicating broad adoption across surgical specialties. Investments in research and development increased by 11% to $197.4 million, highlighting the company's commitment to innovation and future product enhancements. Financially, ISRG maintained a robust balance sheet with $3.3 billion in cash, cash equivalents, and investments, a significant increase from the prior year. The company also continued its stock repurchase program, demonstrating confidence in its financial position and commitment to shareholder returns. Despite some product liability charges and ongoing litigation, the core business demonstrated resilience and growth, positioning Intuitive Surgical favorably within the minimally invasive surgery market.
Feb 2, 2016
2014
Intuitive Surgical Annual Report, Year Ended Dec 31, 2014
Intuitive Surgical, Inc. (ISRG) demonstrated a resilient business model in its 2014 10-K filing, despite a year-over-year revenue decrease to $2.1 billion. This decline was primarily driven by a significant drop in da Vinci Surgical System unit shipments, down 24% to 431 units. However, the company saw growth in recurring revenue streams, with instruments and accessories revenue increasing by 4% to $1.1 billion and service revenue rising by 8% to $429 million. Recurring revenue now constitutes 70% of total revenue, highlighting the growing importance of consumables and services in ISRG's business. The company also faced challenges including a 36% decrease in operating income, impacted by a substantial product liability charge of $82.4 million and ongoing litigation. Despite these headwinds, ISRG continued to invest in research and development ($178 million), reflecting its commitment to innovation, including the launch of the new da Vinci Xi Surgical System. The company maintained a strong cash position with $2.5 billion in cash, cash equivalents, and investments at year-end, supporting its ongoing operations and strategic initiatives.
Feb 6, 2015
2013
Intuitive Surgical Annual Report, Year Ended Dec 31, 2013
Intuitive Surgical, Inc. (ISRG) presented its 2013 annual report, highlighting continued revenue growth driven by a significant increase in da Vinci surgical procedures, particularly in general surgery and gynecology in the U.S., and urology internationally. While total revenue saw a modest 4% increase to $2.27 billion, the company experienced a notable 16% rise in procedures performed to approximately 523,000, underscoring the growing adoption of its robotic surgical systems. However, the company faced headwinds in 2013, including a decrease in U.S. da Vinci Prostatectomy (dVP) procedures due to changes in screening recommendations and treatment patterns, and a slowdown in U.S. benign gynecology procedures attributed to factors like negative media reports and payer trends. System revenue declined by 11%, reflecting longer sales cycles and pressures from healthcare reform and economic uncertainty on hospital capital spending. Despite these challenges, the company maintained a strong financial position with $2.75 billion in cash, cash equivalents, and investments, and continued its focus on research and development to expand product offerings and clinical applications.
Feb 3, 2014
2012
Intuitive Surgical Annual Report, Year Ended Dec 31, 2012
Intuitive Surgical, Inc. (ISRG) in its 2013 10-K filing for the year ended December 30, 2012, reported robust revenue growth of 24% to $2.18 billion, driven by a 25% increase in da Vinci procedures performed globally, reaching approximately 450,000. This growth was fueled by strong performance in U.S. gynecologic and general surgery procedures, as well as international prostatectomies, partially offset by a decline in U.S. prostatectomies due to changes in PSA screening recommendations and disease management. The company continues to see a favorable trend in recurring revenue from instruments, accessories, and service, which now represents 57% of total revenue. This recurring revenue stream is a key indicator of customer stickiness and ongoing system utilization. ISRG also demonstrated strong operational execution with a 26% increase in operating income and a healthy cash flow from operations, ending the year with nearly $3 billion in cash, cash equivalents, and investments. The company continues to invest in research and development to expand its product portfolio, including new instruments and imaging technologies.
Feb 4, 2013
2011
Intuitive Surgical Annual Report, Year Ended Dec 31, 2011
Intuitive Surgical, Inc. (ISRG) reported strong financial performance in its 2011 10-K filing, showcasing continued growth driven by the adoption of its da Vinci Surgical Systems. The company experienced a significant increase in total revenue, up 24% to $1.76 billion, propelled by both system sales and a robust increase in recurring revenue from instruments, accessories, and services. The installed base of da Vinci Surgical Systems grew to 2,132 units, supporting approximately 360,000 procedures performed globally during the year. The company highlights the strategic importance of recurring revenue, which represented 56% of total revenue in 2011, indicating a strong and growing installed base utilization. Key growth drivers included da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP) procedures, alongside an increasing contribution from other surgical specialties like gynecology, cardiothoracic, and general surgery. Intuitive Surgical continues to invest heavily in research and development, focusing on product enhancements and new applications to further drive the adoption of minimally invasive surgery. Looking ahead, the company faces competitive pressures and the inherent risks associated with a novel technology, including market acceptance, regulatory hurdles, and potential economic downturns impacting capital expenditures. However, its expanding installed base, increasing procedure volumes, and focus on recurring revenue streams position it for continued growth. Investors should monitor the company's ability to maintain its technological leadership, navigate regulatory landscapes, and capitalize on the expanding adoption of robotic-assisted surgery across various medical specialties.
Feb 6, 2012
2010
Intuitive Surgical Annual Report, Year Ended Dec 31, 2010
Intuitive Surgical, Inc. (ISRG) reported robust growth for the fiscal year ended December 31, 2010, with total revenue increasing by 34% to $1.41 billion. This growth was primarily driven by increased adoption of the da Vinci Surgical System across various procedures, particularly da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP). The company saw a significant rise in system sales, with 441 units sold, up from 338 in the previous year, and a growing installed base of 1,752 systems worldwide. The company's business model is characterized by both capital equipment sales and recurring revenue from instruments, accessories, and service. Recurring revenue represented 53% of total revenue in 2010, highlighting the sticky nature of their customer base and the ongoing utilization of their systems. Investment in research and development remained strong, with $116 million allocated, indicating a continued focus on product innovation and expansion into new surgical specialties. The company also reported a healthy financial position, with $1.61 billion in cash, cash equivalents, and investments, providing ample resources for future growth and operations.
Feb 1, 2011
2009
Intuitive Surgical Annual Report, Year Ended Dec 31, 2009
Intuitive Surgical, Inc. (ISRG) reported strong performance for the fiscal year ended December 31, 2009. Total revenue reached $1,052 million, a 20% increase year-over-year, driven by a 51% surge in surgical procedures performed using their da Vinci Surgical Systems. This growth was fueled by expanding adoption in key specialties like urology and gynecology, with prostatectomies and hysterectomies being major contributors. The company also saw robust growth in recurring revenue from instruments and accessories, which constituted 53% of total revenue, indicating increasing utilization of their installed base. The company successfully launched its new da Vinci Si Surgical System in Q2 2009, featuring enhanced imaging, an improved user interface, and a dual console for training and collaborative surgery, which is expected to drive future growth. Despite a challenging economic environment in 2009, ISRG demonstrated resilience, with system sales remaining stable and recurring revenue growing significantly. The company ended the year with a strong cash position of $1,172 million, underscoring its financial health and ability to fund ongoing operations and future expansion.
Jan 29, 2010
2008
Intuitive Surgical Annual Report, Year Ended Dec 31, 2008
Intuitive Surgical Inc. (ISRG) presented a strong financial performance in its 2008 10-K filing, showcasing significant revenue growth driven by the increasing adoption of its da Vinci Surgical System. The company reported a 46% increase in total revenue, reaching $874.9 million, with recurring revenue from instruments and accessories, and services, contributing 48% of the total. The installed base of da Vinci Surgical Systems grew to 1,111 units, facilitating approximately 136,000 procedures globally, with prostatectomies and hysterectomies being the dominant procedures. Despite a slowdown in system sales in the fourth quarter of 2008 due to the economic environment, the company maintained a healthy gross profit margin of 71% and a robust operating income of $310.8 million. ISRG's financial position remained strong with $901.9 million in cash, cash equivalents, and investments. The company continues to invest heavily in research and development, indicating a commitment to innovation and maintaining market leadership in robotic-assisted surgery.
Feb 6, 2009
2007
Intuitive Surgical Annual Report, Year Ended Dec 31, 2007
Intuitive Surgical, Inc. (ISRG) demonstrated robust financial performance in its 2007 10-K filing, highlighted by significant revenue growth driven by the increasing adoption of its da Vinci Surgical System. The company reported a 61% increase in revenue to $600.8 million, with recurring revenue from instruments and accessories growing by 66%. This growth was fueled by a 42% increase in system unit sales and the successful introduction of new products like the da Vinci S Surgical System with HD vision. The company's strategy to establish da Vinci surgery as the standard for complex procedures is showing traction, particularly in urologic and gynecologic surgeries, with prostatectomies and hysterectomies being key drivers. ISRG continues to invest in research and development, indicating a commitment to technological advancement and market leadership. The company's strong cash position and operational efficiency provide a solid foundation for future growth, despite facing competitive pressures and the inherent complexities of regulatory approvals and long sales cycles in the medical device industry.
Feb 14, 2008
2006
Intuitive Surgical Annual Report, Year Ended Dec 31, 2006
Intuitive Surgical, Inc. (ISRG) demonstrated robust growth in 2006, with revenue increasing by 64% to $372.7 million. This growth was primarily driven by the expanding adoption of its da Vinci Surgical System across various specialties, notably urology and gynecology. The company's business model successfully balances capital equipment sales with recurring revenue from instruments, accessories, and service contracts, with recurring revenue constituting 45% of total revenue in 2006. Significant product development included the launch of the da Vinci S Surgical System in early 2006, which contributed substantially to system sales, and the introduction of a high-definition 3-D vision system in early 2007. Financially, Intuitive Surgical reported strong performance with operating income increasing by 56% and substantial cash flow generation. The company ended the year with a healthy cash balance of $330.3 million, providing financial flexibility. The company is strategically focused on establishing da Vinci surgery as the standard of care for complex procedures and continues to invest in research and development to enhance its technology and expand its product offerings. Key risks include market acceptance, competition, and regulatory hurdles, though the company is actively managing these challenges.
Feb 15, 2007
2005
Intuitive Surgical Annual Report, Year Ended Dec 31, 2005
Intuitive Surgical Inc. demonstrated significant growth in 2005, with sales increasing by 64% to $227.3 million, driven by the expanding adoption of its da Vinci Surgical System. The company saw strong performance across multiple surgical specialties, particularly in urology, and noted a substantial increase in recurring revenue from instruments, accessories, and service, which constituted 45% of total sales. Key strategic achievements included expanding FDA clearances for broader urologic and gynecologic procedures, and the successful market penetration in the radical prostatectomy segment, capturing approximately 20% of the U.S. market by year-end. Financially, Intuitive Surgical reported a substantial increase in operating income to $68.8 million, a 225% jump from the previous year, and improved gross profit margins to 68%. The company also strengthened its financial position with a significant increase in cash, cash equivalents, and investments, ending the year with over $200 million. Significant investments were made in expanding facilities to support future growth, including the acquisition of a new campus. The company launched the da Vinci S Surgical System in early 2006, signaling continued innovation and a commitment to enhancing its product line.
Mar 15, 2006
2004
Intuitive Surgical Annual Report, Year Ended Dec 31, 2004
Intuitive Surgical Inc. (ISRG) reported significant year-over-year revenue growth for the fiscal year ending December 31, 2004, with sales reaching $138.8 million, a 51% increase from the previous year. The company achieved its first profitable year, reporting a net income of $23.5 million, or $0.67 per diluted share, a marked improvement from the net loss of $9.6 million in 2003. This financial turnaround was driven by increased adoption of the da Vinci Surgical System, particularly in urologic procedures, and substantial growth in recurring revenue from instruments and services, which now constitute 43% of total sales. The company shipped 76 da Vinci Surgical Systems in 2004, a 25% increase over 2003. The gross margin also improved significantly to 63.4% in 2004 from 48.0% in 2003, reflecting manufacturing efficiencies and cost reductions. Operating expenses grew at a slower pace than revenue, indicating operational leverage. Key strategic achievements in 2004 included FDA clearance for coronary anastomosis procedures and the launch of new 5mm instruments, expanding the system's clinical capabilities.
Mar 16, 2005
2003
Intuitive Surgical Annual Report, Year Ended Dec 31, 2003
Intuitive Surgical, Inc. (ISRG) filed its 2003 10-K report on March 11, 2004, detailing a transformative year characterized by the significant acquisition of Computer Motion, Inc. and continued growth in its da Vinci Surgical System sales. The company reported increased total sales of $91.7 million, up from $72.0 million in 2002, driven by both product and service revenue. Despite this top-line growth, ISRG reported a net loss of $9.6 million for the year, an improvement from a $18.4 million loss in 2002. This loss is attributed to substantial operating costs, including significant restructuring charges and impairment charges related to the Computer Motion acquisition, which aimed to consolidate operations and achieve substantial cost savings. Key strategic initiatives in 2003 included the launch of a fourth surgical arm upgrade for the da Vinci system and a successful follow-on stock offering that provided $77.7 million in net proceeds, bolstering the company's cash position to $112.9 million. The company is focused on establishing its "Intuitive Surgery" as the standard for complex procedures and is investing in R&D to enhance its technology and expand its product portfolio. Despite the net loss, the increasing proportion of revenue from instruments and services, alongside strategic acquisitions and product enhancements, indicates a positive trajectory for future revenue growth and operational efficiency.
Mar 12, 2004
2002-A2
Intuitive Surgical Annual Report (Amendment), Year Ended Dec 31, 2002
Intuitive Surgical's FY2002 10-K (filed May 30, 2003) shows a company still in an early commercialization phase for its da Vinci Surgical System. Revenue rose 39% to $72.0 million in 2002, driven by 60 system sales (versus 49 in 2001) at an average selling price of $948,000 and recurring instrument, accessory, and service revenue that grew 116% to $15.1 million. Gross margin improved to 52% from 45%, yet the company still posted a net loss of $18.4 million, and cash, equivalents and short-term investments fell to $50.8 million from $66.7 million. Management states that current resources are sufficient through 2003, but operating losses and cash burn remain a concern. The dominant strategic event is the pending merger with rival Computer Motion, announced March 7, 2003. Intuitive expects to issue about 15.6 million shares (roughly 30% of the combined company to Computer Motion holders, per the filing's estimate) and projects roughly $18 million in annual pre-tax cost savings beginning late 2003. The deal would also end a sprawling set of patent suits between the two companies, though the litigation is currently stayed through August 31, 2003 and could resume if the merger fails. Investors should weigh the synergy and litigation-resolution upside against dilution, integration risk, and the uncertain outcome of pending patent matters, including the Brookhill-Wilk case, which the Federal Circuit reversed in April 2003. Longer term, the company's thesis depends on surgeon adoption of its platform for complex procedures, expanding FDA clearances, and growing the recurring revenue base from instruments and service. Heavy reliance on high-priced capital systems, a small number of sales per quarter, sole-source components, and reimbursement uncertainty all remain material risks highlighted in the filing.
May 30, 2003
2002-A
Intuitive Surgical Annual Report (Amendment), Year Ended Dec 31, 2002
Intuitive Surgical's 2002 10-K (filed May 9, 2003) shows a company still in early commercialization of the da Vinci Surgical System. Sales grew 39% to $72.0 million in 2002, driven by 60 system placements (versus 49 in 2001) and recurring instrument, accessory and service revenue, which rose 116% to $15.1 million and reached 21% of sales. Gross margin improved to 52% from 45%, but the company still lost $18.4 million for the year, with operating loss essentially flat at $20.2 million despite the revenue growth, because SG&A rose 36% and R&D rose 21%. Cash, equivalents and short-term investments fell to $50.8 million from $66.7 million, and management expects liquidity to be sufficient only through 2003 absent additional financing. The dominant event in the filing is the pending all-stock merger with rival Computer Motion, announced March 7, 2003. Intuitive expects to issue about 14.7 million shares, leaving its current holders with roughly 72% of the combined company. Management projects about $18 million in annual pre-tax cost savings from late 2003, largely from headcount reductions. Intuitive also agreed to bridge-loan up to $7.3 million to Computer Motion, which itself reported a $21.2 million 2002 net loss and only $2.6 million in cash. Pending patent litigation between the two companies has been stayed through August 31, 2003 pending closing. Investors should weigh several risks: continued losses, dependence on high-priced capital equipment with long sales cycles, a Wilk patent appeal that was reversed in April 2003, unresolved Computer Motion patent claims (including a $4.4 million jury verdict in Intuitive's favor on a separate IBM-licensed patent), and the merger's dilution and integration risk. Reimbursement for newer procedures and the need for FDA clearance of additional indications also remain open items.
May 9, 2003
2002
Intuitive Surgical Annual Report, Year Ended Dec 31, 2002
Intuitive Surgical's 2002 10-K shows a company still in early commercialization of the da Vinci Surgical System. Sales rose 39% to $72.0 million on 60 system sales (vs. 49 in 2001), with average selling price rising to $948,000. Gross margin improved to 52% from 45%, and recurring instrument, accessory and service revenue grew to 21% of sales. Despite this progress, the company still lost $18.4 million for the year, cash and short-term investments fell to $50.8 million, and cumulative system placements reached 149. The dominant investor issue is the pending merger with Computer Motion, announced March 7, 2003. Intuitive expects to issue about 14.7 million shares, leaving current holders with roughly 72% and former Computer Motion holders with about 28%, and it projects $18 million in annual pre-tax cost savings. The deal also resolves a long-running patent war: the litigation is stayed through August 31, 2003 and would be dismissed if the merger closes. Intuitive has also extended a $7.3 million bridge loan to Computer Motion. Combined cash is projected below $35 million, so funding and dilution are central considerations. Key risks include unresolved patent litigation (notably the Computer Motion and Brookhill-Wilk suits, which could bar product sales if lost), ongoing losses, dependence on a high-price capital product with lengthy sales cycles, and limited history of profitability. The company says current resources should suffice through 2003, with additional financing possibly needed thereafter.
Mar 28, 2003
2001
Intuitive Surgical Annual Report, Year Ended Dec 31, 2001
Intuitive Surgical's 2001 10-K shows a company still in early commercialization of its da Vinci Surgical System. Revenue more than doubled to $51.7 million in 2001 from $26.6 million in 2000, driven by system sales rising to 49 units from 28. Gross margin improved to 45% from 32%, helped by manufacturing efficiencies, though the company still posted a net loss of $16.7 million (EPS of -$0.47), narrowing from $18.5 million in 2000. Operating expenses grew 42% to $43.8 million as selling, general and administrative costs rose 57% to $30.0 million to build out the sales and field service organization. The balance sheet is thinner than the headline numbers suggest. Cash, equivalents and short-term investments fell to $66.7 million from $89.4 million, and operating cash burn was $18.6 million. Management states that current resources are sufficient through 2003, but it also warns that additional financing may be needed afterward. Accounts receivable jumped to $13.2 million, a sign that revenue growth is consuming working capital. The main investor risk is litigation. Computer Motion's suit (which seeks treble damages and an injunction) and Brookhill-Wilk's appeal could threaten the company's ability to sell its products if the company loses. Several of these matters are unresolved, and the company says it cannot estimate potential losses. Regulatory progress is also a key variable: the FDA clearances obtained so far cover laparoscopic, thoracoscopic, and prostatectomy use, while cardiac indications remain under investigation.
Apr 1, 2002